Search results
Results from the WOW.Com Content Network
It has the following product in pipeline: Cabiralizumab, FPA150, Bemarituzumab and Immuno-Oncology.Five Prime Therapeutics shares were trading up 20.53% at $5.30 on Monday. The stock has a 52-week ...
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of 20.80% and 29.22%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of -21.31% and -41.49%, respectively, for the quarter ended September 2020. ... Do the numbers hold clues to what lies ahead ...
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
Change is in the air. A new President-elect and the possibility of an end to the pandemic. Some things, however, will always stay the same.Like small cap biotech stocks skyrocketing following the ...
For premium support please call: 800-290-4726 more ways to reach us
Shares of Five Prime Therapeutics (NASDAQ:FPRX) were unchanged in after-market trading after the company reported Q3 results.Quarterly Results Earnings per share increased 28.16% over the past ...